Session Description: This session will review the development and dissemination of a longitudinal treatment outcomes report for a national office-based opioid treatment provider. Lessons learned from the 2020 report and updates for the 2021 report will be highlighted along with future initiatives. The first report based on the 2020 Ideal Option patient population consisting of over 24,400 patients was published featuring patient demographics, substance of use, retention, medication adherence, and treatment outcomes. The patient outcomes emphasize the importance of comprehensive definitive urine drug tests as essential components of effective treatment. Our treatment model incorporates objective toxicology directly into clinical protocols to motivate patients, monitor medication adherence, and reduced polysubstance use. The main intention of the longitudinal outcome reporting is to increase industry transparency and evaluate treatment progress with real-world data to allow for programmatic, policy, and payment interventions designed through data driven solutions. Longitudinal outcomes reporting can directly influence clinical practice by reinforcing the use of objective measurements for tracking clinical progress and help clinicians adapt treatment models. Ideal Option strives to make data available to help set a national standard for objective quality evaluation for increased accountability and program improvement measures within the field of substance use treatment.
This session has been approved by NBCC for NBCC credit.
Learning Objectives:
After this activity participants should be able to
Demonstrate how to define and measure meaningful outcomes for outpatient-based substance use disorder treatment.
Recognize how to leverage existing health record date to develop appropriate outcome metrics.
Identify the purpose and goals of providing a publicly available outcomes report.
